Goldman Sachs maintains Vir Biotech at 'buy' with a price target of $28.00

  • Investing.com
Goldman Sachs maintains Vir Biotech at 'buy' with a price target of $28.00

An analyst from Goldman Sachs maintained Vir Biotech (NASDAQ: VIR ) at 'buy' with a price target of $28.00 from a prior price target of %currency%%price%.

Prior to this rating, Vir Biotech had 8 buy ratings, 1 hold ratings, and 0 sell ratings.

For consensus analyst estimates and price targets on Vir Biotech, click here. For more news on Vir Biotech, click here.

Vir Biotech's stock price closed at $12.70. They are down -49.02% in the last month and down -56.16% in the last 12 months.

According to Investing Pro, Vir Biotech's fair value is $24.59, an upside of 93.60%. Vir Biotech's fair value comes with a medium degree of uncertainty, according to InvestingPro.

Check out Vir Biotech's recent earnings performance and financials here.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100

Related Articles